Clinical Trial Search

Primary: Change From Baseline to Week 24 in Distance Walked as Assessed by the Six-minute Walk Test (6MWT) Distance — 12.40; 20.11 meters

Primary: Time to Death or Distant Metastasis — 30.7 months

Primary: Incidence of Treatment-Emergent Adverse Events — 0; 0; 0; 0 Participants

Primary: Percentage of Participants Who Achieve a PPPASI-50 at Week 16 — 40.9; 78.3 Percentage of Partcipants — p=0.0003

Primary: Percentage of Participants With Recurrence of Focal Segmental Glomerulosclerosis (rFSGS) or Death or Graft Loss or Lost to Follow-up Through 3 Months Post Transplant…

Primary: Change From Baseline (Day 1) in Maximal Tolerated Volume Consumed During the Nutrient Satiety Test at Day 14 — 293.5; 345.6; 1.3; 2.0 mL — p=0.9030

Primary: Number of Patients With Adverse Events (AEs) — 3; 8; 3 Participants

Primary: Percent of Participants With Best Overall Objective Response or Complete Response/Partial Response (CR/PR) — 89 percentage of participants

Primary: Stage 1 Main Phase: Overall Response Rate (ORR) — 37.5; 14.3; 33.3; 50.0 Percentage of Participants

Primary: Change in Peak Bicarbonate Concentration, Measured Using Endoscopic Pancreatic Function Test (ePFT) — -8.20; 5.50 mmol/l

Primary: Change in Composite Drive Score (CDS) From Pre-smoking Simulation — -.09; .12; .01; -.17 z-score — p=<0.001

Primary: Left Ventricular Ejection Fraction (LVEF) — 58.1; 57.9 percent ejected from LV per heartbeat — p=0.84

Primary: Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12 — -1.92; -2.75; -2.75; -1.39 VMS per day

Primary: Percentage of Participants With CMV Viremia Through 1 Year Post First Study Drug Injection — 35.6; 35.6; 5.5; 0 Percentage of Paticipants — p=0.307

Primary: Body Mass Index — 10.1; 4.6 percentage (body mass index)